Evidence map›Paper›PMID 17701167›Full record

Trial reportEuropean journal of clinical pharmacology2007

Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.

L Andrén, A Andreasson, R Eggertsen

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Diverse Therapeutic Potentials of Hypericin: An In-Depth Review.Current topics in medicinal chemistry · 2025
    Review
  4. Documentary Analysis ofPharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Iranian journal of basic medical sciences · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Drug interactions with herbal medicines.Clinical pharmacokinetics · 2012
    Review
  16. Article
  17. Review
  18. What is the true risk of a pharmacokinetic drug-drug interaction?European journal of clinical pharmacology · 2007
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

L AndrénDepartment of Medicine/Clinical Pharmacology, Gothenburg University, Sahlgrenska University Hospital, Vita Stråket 11, S-413 45, Gothenburg, Sweden. lennart.andren@pharm.gu.se
A Andreasson
R Eggertsen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to assess the effect of treatment with a St. John's wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study.

methodsSixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10-40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint.

resultsAll patients completed the study. The St. John's wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p = 0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p = 0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p = 0.49) or in triglycerides (1.87 mmol/l and 1.94 mmol/l, p = 0.60). No product-related side effects were reported

conclusionAn interaction was observed between the studied St.-John's-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John's wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.

Indexed as

Herb-Drug InteractionsHypericumAgedAtorvastatinATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1CholesterolCholesterol, HDLCholesterol, LDLCross-Over StudiesCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemEnzyme InductionFemaleHeptanoic AcidsHumansABCB1 protein, humanAtorvastatinATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1CholesterolCholesterol, HDLCholesterol, LDLCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPlant PreparationsPyrrolesTriglycerides

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.